Opinion|Videos|July 22, 2024
Transition of Care in Young Adults With Spinal Muscular Atrophy
Medical professionals explore the challenges and considerations associated with patients with spinal muscular atrophy (SMA) transitioning to independent living, emphasizing the importance of maintaining continuity of care and addressing potential adherence issues to ensure optimal disease management.
Advertisement
Episodes in this series
- When transitioning care from a parent to patients living on their own, what are some important considerations to ensure continuity of care?
- What gaps do you observe in your practice and how do you mitigate them?
Advertisement
Related to this article
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
2
PrimeC Lowers Neuron-Derived TDP-43, Informing Phase 3 PARAGON Trial in ALS
3
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
4
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
5